Design Therapeutics Inc. Common Stock (DSGN)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with earnings and assets. Design Therapeutics offers little of either in a conventional sense. It is a clinical-stage biotech with no revenue in the filed periods, and it lost $69.8 million in fiscal 2025, $49.6 million in fiscal 2024, and $66.9 million in fiscal 2023. The most recent quarter, Q2 2026 ended 2026-06-30, showed a $20.2 million net loss and diluted EPS of -$0.32. Trailing free cash flow is -$55.1 million, a -9.0% FCF yield on the $612.0 million market cap. The stock closed at $9.78 on 2026-10-13, and FairStock puts P/E at -8.29, P/B at 3.03, ROE at -34.13%, and ROCE at -22.53%. Those are not bargains; they are symptoms of an unproven business. The balance sheet shows low leverage, with D/E of 0.01 and an Altman Z-Score of 26.61, and only 55 employees, so capital may be focused. But Piotroski F-Score is 0/9 and the FairStock score is 26/100. The Lynch category is none because losses in each of the last four years mean no category fits. The GeneTAC platform and Friedreich Ataxia program could become valuable if trials succeed, but that is a binary scientific bet, not a durable moat. Without revenue, profits, or positive cash flow, I cannot calculate a margin of safety from the numbers. I would watch cash burn, trial data, and financing needs—not the stock price. This is speculation on future medicine, not Graham-style value.

In plain English: Design Therapeutics is a small clinical-stage biotech with 55 employees testing experimental medicines for inherited genetic diseases, including Friedreich Ataxia. It has no revenue and has lost money in each of the last several years, including a $69.8 million loss in fiscal 2025 and a $20.2 million loss in the quarter ended June 30, 2026. At $9.78, the price looks expensive against its accounting value and current losses; any real value depends on whether its drugs succeed in trials.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer